兒科
  • 王碩郁

    兒科 :
    門診掛號  

  • 現職

      • 台東馬偕醫院兒科主治醫師 

    主要學歷

      • 國立陽明大學醫學系學士
      • 長庚大學臨床醫學研究所博士

    主要經歷

      • Feb, 2020 –now高雄醫學大學附設中和紀念醫院小兒部小兒遺傳內分泌新陳代謝科主治醫師 (現任)
      • Oct, 2007– Oct, 2019奇美醫院兒科部主治醫師
      • Sep, 2006 – Aug, 2007 嘉義縣太保市衛生所主任
      • Aug, 2003– Jul, 2005 台大醫院小兒內分泌科臨床研究員
      • Aug, 1999– Aug, 2006 高雄榮民總醫院兒童醫學部住院醫師

主治項目或專長

MAJOR SERVICE

兒童糖尿病、兒童甲狀腺疾病、兒童生長發育、身材矮小、青春期發育延遲、性早熟、中樞性尿崩症、兒童肥胖、兒童腎上腺及其他內分泌相關疾病  


論文研究

  • (A)First Author

  • 1.  Wang SY, Wang CT, Tien KJ, Chang CC, Liu TH. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs. Kaohsiung J Med Sci. 2020;36:281-286.
  • 2. Wang SY, Wei YH, Shieh DB, Lin LL, Cheng SP, Wang PW, Chuang JH. 2-Deoxy-D-glucose can complement doxorubicin and sorafenib to suppress the growth of papillary thyroid carcinoma cells. PLoS One. 2015; 10: e0130959.
  • 3. Huang CC*, Wang SY*, Lin LL, Wang PW, Chen TY, Hsu WM, Lin TK, Liou CW, Chuang JH. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth. (*Co-first author). Dis Model Mech. 2015;8: 1247-1254. 
  • 4. Wang SY, Tung YC, Tsai WY, Chien YH, Lee JS, Hwu WL. Slipped capital femoral epiphysis as a complication of growth hormone therapy. J Formos Med Assoc. 2007; 106: S46-50. 
  • 5. Wang SY, Tung YC, Tsai WY, Lee JS, Hsiao PH. Long-term outcome of hormonal status in Taiwanese children with Hashimoto's thyroiditis. Eur J Pediatr. 2006; 165:481-483.